Works matching DE "TELAPREVIR"

Results: 203

Ombitasvir/paritaprevir/r, dasabuvir and ribavirin for cirrhotic HCV patients with thrombocytopaenia and hypoalbuminaemia.

Published in:

Liver International, 2015, v. 35, n. 11, p. 2358, doi. 10.1111/liv.12931

By:

Forns, Xavier;
Poordad, Fred;
Pedrosa, Marcos;
Berenguer, Marina;
Wedemeyer, Heiner;
Ferenci, Peter;
Shiffman, Mitchell L.;
Fried, Michael W.;
Lovell, Sandra;
Trinh, Roger;
Lopez ‐ Talavera, Juan Carlos;
Everson, Gregory

Publication type:

Article

Triple therapy with boceprevir or telaprevir in a European cohort of cirrhotic HIV/ HCV genotype 1-coinfected patients.

Published in:

Liver International, 2015, v. 35, n. 9, p. 2090, doi. 10.1111/liv.12799

By:

Miailhes, Patrick;
Gilbert, Camille;
Lacombe, Karine;
Arends, Joop E.;
Puoti, Massimo;
Rockstroh, Jürgen K.;
Sogni, Philippe;
Fontaine, Hélène;
Rosenthal, Eric;
Winnock, Maria;
Loko, Marc‐Arthur;
Wittkop, Linda;
Dabis, François;
Salmon, Dominique

Publication type:

Article

Drug-drug interactions of telaprevir and boceprevir in HCV-monoinfected and HIV/ HCV-coinfected patients can modify the adherence.

Published in:

Liver International, 2015, v. 35, n. 5, p. 1557, doi. 10.1111/liv.12729

By:

González‐Colominas, Elena;
Broquetas, Teresa;
Retamero, Alexandra;
García‐Retortillo, Montserrat;
Cañete, Nuria;
Coll, Susanna;
Pellicer, Rosa;
Giménez, Maria D.;
Cabrero, Beatriz;
Bory, Felipe;
Knobel, Hernando;
Salas, Esther;
Solà, Ricard;
Carrión, José A.

Publication type:

Article

Proving risk factors with laboratory data may be more valuable.

Published in:

Liver International, 2015, v. 35, n. 2, p. 680, doi. 10.1111/liv.12677

By:

Coban, Mehmet;
Sertoglu, Erdim

Publication type:

Article

Low-density lipoprotein and other predictors of response with telaprevir-based therapy in treatment-experienced HCV genotype 1 patients: REALIZE study.

Published in:

Liver International, 2015, v. 35, n. 2, p. 448, doi. 10.1111/liv.12703

By:

Berg, Thomas;
Andreone, Pietro;
Pol, Stanislas;
Roberts, Stuart;
Younossi, Zobair;
Diago, Moises;
Lawitz, Eric J.;
Focaccia, Roberto;
Foster, Graham R.;
Horban, Andrzej;
Lonjon ‐ Domanec, Isabelle;
DeMasi, Ralph;
Picchio, Gaston;
Luo, Donghan;
De Meyer, Sandra;
Zeuzem, Stefan

Publication type:

Article

Telaprevir drug monitoring during antiviral therapy of hepatitis C graft infection after liver transplantation.

Published in:

Liver International, 2015, v. 35, n. 1, p. 176, doi. 10.1111/liv.12532

By:

Farnik, Harald;
Zimmermann, Tim;
Herrmann, Eva;
Bechstein, Wolf O.;
Kronenberger, Bernd;
Galle, Peter R.;
Labocha, Sandra;
Ferreiros, Nerea;
Geisslinger, Gerd;
Zeuzem, Stefan;
Sarrazin, Christoph;
Welker, Martin W.

Publication type:

Article

Diabetes mellitus and advanced liver fibrosis are risk factors for severe anaemia during telaprevir-based triple therapy.

Published in:

Liver International, 2014, v. 34, n. 7, p. 1018, doi. 10.1111/liv.12342

By:

Crismale, James F.;
Martel-Laferrière, Valérie;
Bichoupan, Kian;
Schonfeld, Emily;
Pappas, Alexis;
Wyatt, Christina;
Odin, Joseph A.;
Liu, Lawrence U.;
Schiano, Thomas D.;
Perumalswami, Ponni V.;
Bansal, Meena;
Dieterich, Douglas T.;
Branch, Andrea D.

Publication type:

Article

How to optimize HCV therapy in genotype 1 patients: predictors of response.

Published in:

Liver International, 2013, v. 33, p. 23, doi. 10.1111/liv.12053

By:

Petta, Salvatore;
Craxì, Antonio

Publication type:

Article

Optimal treatment with telaprevir for chronic HCV infection.

Published in:

Liver International, 2013, v. 33, p. 3, doi. 10.1111/liv.12079

By:

Jesudian, Arun B.;
Jacobson, Ira M.

Publication type:

Article

Patients with HCV and F1 and F2 fibrosis stage: treat now or wait?

Published in:

Liver International, 2013, v. 33, p. 105, doi. 10.1111/liv.12066

By:

Shiffman, Mitchell L.;
Benhamou, Yves

Publication type:

Article

Protease inhibitor-based triple therapy in chronic hepatitis C: guidelines by the French Association for the Study of the Liver.

Published in:

Liver International, 2012, v. 32, n. 10, p. 1477, doi. 10.1111/j.1478-3231.2012.02856.x

By:

Leroy, Vincent;
Serfaty, Lawrence;
Bourlière, Marc;
Bronowicki, Jean-Pierre;
Delasalle, Patrick;
Pariente, Alexandre;
Pol, Stanislas;
Zoulim, Fabien;
Pageaux, Georges-Philippe

Publication type:

Article

Immobilised whole-cell recombinant monoamine oxidase biocatalysis.

Published in:

Applied Microbiology & Biotechnology, 2015, v. 99, n. 3, p. 1229, doi. 10.1007/s00253-014-5983-1

By:

Zajkoska, Petra;
Rosenberg, Michal;
Heath, Rachel;
Malone, Kirk;
Stloukal, Radek;
Turner, Nicholas;
Rebroš, Martin

Publication type:

Article

Comparison of Daclatasvir and Asunaprevir for Chronic HCV 1b Infection with Telaprevir and Simeprevir plus Peginterferon and Ribavirin, with a Focus on the Prevention of Occurrence and Recurrence of Hepatocellular Carcinoma.

Published in:

Oncology, 2015, v. 89, p. 42, doi. 10.1159/000440630

By:

Sugimoto, Kayo;
Kim, Soo Ryang;
Kim, Soo Ki;
Imoto, Susumu;
Tohyama, Madoka;
Kim, Ke Ih;
Ohtani, aya;
Hatae, Takashi;
Yano, Yoshihiko;
Kudo, Masatoshi;
Hayashi, Yoshitake

Publication type:

Article

Efficacy and Safety of Telaprevir-Based Antiviral Treatment for Elderly Patients with Hepatitis C Virus.

Published in:

Oncology, 2014, v. 87, p. 110, doi. 10.1159/000368154

By:

Takita, Masahiro;
Hagiwara, Satoru;
Kudo, Masatoshi;
Kouno, Masashi;
Chishina, Hirokazu;
Arizumi, Tadaaki;
Kitai, Satoshi;
Yada, Norihisa;
Inoue, Tatsuo;
Minami, Yasunori;
Ueshima, Kazuomi

Publication type:

Article

Potential P-glycoprotein Pharmacokinetic Interaction of Telaprevir With Morphine or Methadone.

Published in:

Journal of Pain & Palliative Care Pharmacotherapy, 2013, v. 27, n. 3, p. 261, doi. 10.3109/15360288.2013.803512

By:

Fudin, Jeffrey;
Fontenelle, Dania Vanesta;
Fudin, Hannah Rebecca;
Carlyn, Cynthia;
Hinden, Debra Ann;
Ashley, Christopher C.

Publication type:

Article

EDITORIAL.

Published in:

2016

By:

TABAK, Fehmi;
ALTINDİŞ, Mustafa

Publication type:

Editorial

Telaprevir-based Triple Therapy for Retreatment of Chronic Hepatitis C Patients with Genotype Four Followed in Our Clinic.

Published in:

Viral Hepatitis Journal / Viral Hepatit Dergisi, 2016, v. 22, n. 2, p. 58, doi. 10.4274/vhd.94695

By:

DURSUN, Zehra BEŞTEPE;
ÇELİK, İlhami

Publication type:

Article

Partial Splenic Embolization may be an Option to Overcome Thrombocytopenia Interfering with Triple Therapy in HCV (+) Cirrhotic Patients: A Case Report.

Published in:

Viral Hepatitis Journal / Viral Hepatit Dergisi, 2015, v. 21, n. 3, p. 102, doi. 10.4274/vhd.81300

By:

ASİL, Mehmet;
BIYIK, Murat;
ÇİFÇİ, Sami;
SAYIN, Serhat;
UÇAR, Ramazan;
ÖZBEK, Orhan;
ATASEVEN, Hüseyin;
POLAT, Hakkı;
DEMİR, Ali

Publication type:

Article

New Triple Therapy for Chronic Hepatitis C: Real Life Clinical Experience in a Community Setting.

Published in:

Hawaii Journal of Medicine & Public Health, 2013, v. 72, n. 9, p. 6

By:

Akiyama, Matthew J.;
Piotrowski, Joy I.;
Roytman, Marina M.;
Siu M. A. Chan;
Hong, Leena K.;
Huddleston, Leslie;
Trujillo, Ruby;
Tsai, Naoky C. S.

Publication type:

Article

Efficacy and safety of telaprevir and boceprevir in patients with hepatitis C genotype 1: a meta-analysis.

Published in:

Journal of Clinical Pharmacy & Therapeutics, 2014, v. 39, n. 1, p. 14, doi. 10.1111/jcpt.12106

By:

Park, C.;
Jiang, S.;
Lawson, K. A.

Publication type:

Article

Boceprevir and telaprevir: new treatments for chronic hepatitis C.

Published in:

Prescriber, 2012, v. 23, n. 23/24, p. 42, doi. 10.1002/psb.998

By:

Chaplin, Steve;
Dusheiko, Geoffrey

Publication type:

Article

Hepatitis C: why the low uptake of boceprevir and telaprevir?

Published in:

Prescriber, 2012, v. 23, n. 23/24, p. 6, doi. 10.1002/psb.992

By:

Gore, Charles

Publication type:

Article

Comment to “Telaprevir Experience From Turkey”.

Published in:

2015

By:

Akar, Tarik;
Malkoc, Dilek;
Aydemir, Selim

Publication type:

Letter to the Editor

Increased Ribavirin Bioavailability Associated With Telaprevir Use in Hepatitis C Patients Treated With PEGylated -Interferon/Ribavirin/Telaprevir Triple Therapy.

Published in:

Hepatitis Monthly, 2015, v. 15, n. 9, p. 1, doi. 10.5812/hepatmon.28879

By:

Pradat, Pierre;
Virlogeux, Victor;
Maynard, Marianne;
Leclercq, Mathilde;
Hatu, Giorgiana;
Amiri, Majid;
Lebosse, Fanny;
Miailhes, Patrick;
Zoulim, Fabien;
Gagnieu, Marie-Claude;
Bailly, François

Publication type:

Article

Integrated quality by design (QbD) and design of experiments (DoE) approach for UFLC determination of telaprevir in rat serum.

Published in:

Journal of Liquid Chromatography & Related Technologies, 2017, v. 40, n. 19, p. 951, doi. 10.1080/10826076.2017.1387558

By:

Panda, Sagar Suman;
Sharma, Khusbu;
Mohanty, Bijeta;
Bera, Ravi Kumar Venkata Varaha;
Acharjya, Sasmita Kumari;
Beg, Sarwar

Publication type:

Article

Direct-acting antiviral therapies for hepatitis C genotype 1 infection: a multiple treatment comparison meta-analysis.

Published in:

QJM: An International Journal of Medicine, 2013, v. 106, n. 2, p. 153, doi. 10.1093/qjmed/hcs214

By:

Cooper, C.;
Lester, R.;
Thorlund, K.;
Druyts, E.;
El Khoury, A.C.;
Yaya, S.;
Mills, E.J.

Publication type:

Article

THE NEW STANDARD OF CARE IN HCV TREATMENT.

Published in:

Johns Hopkins Advanced Studies in Medicine, 2014, v. 14, n. 1, p. 8

By:

Sulkowski, Mark

Publication type:

Article

A Translational Study of Resistance Emergence Using Sequential Direct-Acting Antiviral Agents for Hepatitis C Using Ultra-Deep Sequencing.

Published in:

American Journal of Gastroenterology (Springer Nature), 2013, v. 108, n. 9, p. 1464, doi. 10.1038/ajg.2013.205

By:

Abe, Hiromi;
Hayes, C Nelson;
Hiraga, Nobuhiko;
Imamura, Michio;
Tsuge, Masataka;
Miki, Daiki;
Takahashi, Shoichi;
Ochi, Hidenori;
Chayama, Kazuaki

Publication type:

Article

HCV RNA Viral Load Assessments in the Era of Direct-Acting Antivirals.

Published in:

American Journal of Gastroenterology (Springer Nature), 2013, v. 108, n. 4, p. 471, doi. 10.1038/ajg.2012.248

By:

Cobb, Bryan;
Pockros, Paul J;
Vilchez, Regis A;
Vierling, John M

Publication type:

Article

Computer-aided identification of a series of novel ligands showing high potency as hepatitis C virus NS3/4A protease inhibitors.

Published in:

Bulletin of the National Research Centre, 2021, v. 45, n. 1, p. N.PAG, doi. 10.1186/s42269-020-00467-w

By:

Ejeh, Stephen;
Uzairu, Adamu;
Shallangwa, Gideon Adamu;
Abechi, Stephen E.

Publication type:

Article

Telaprevir-Induced DRESS Syndrome Associated With Salmonella typhi.

Published in:

ACG Case Reports Journal, 2015, v. 2, n. 2, p. 79, doi. 10.14309/crj.2015.10

By:

Akar, Tarık;
Kilavuz, Beyza;
Malkoç, Dilek;
Dindar, Gökhan;
Aynioğlu, Aynur

Publication type:

Article

Evaluation of the health-related quality of life using the 36-item short form health survey in patients with chronic hepatitis C receiving pegylated interferon/ribavirin/telaprevir triple treatment.

Published in:

Experimental & Therapeutic Medicine, 2016, v. 12, n. 5, p. 3353, doi. 10.3892/etm.2016.3785

By:

MITSUYUKI SUZUKI;
TORU ISHIKAWA;
AI SAKUMA;
SATOSHI ABE;
HIROKO ABE;
FUJIKO KOYAMA;
TOMOMI NAKANO;
AYA UEKI;
HIROHITO NOGUCHI;
ERINA HASEGAWA;
SHIORI YAMAGATA;
MIKI KOBAYASHI;
KAZUTAKA OHASHI;
HIROSHI HIROSAWA;
TAKAKO FUKAZAWA;
YUKA MARUYAMA;
TOSHIAKI YOSHIDA

Publication type:

Article

Analysis of renal function during telaprevir-based triple therapy for chronic hepatitis C.

Published in:

Experimental & Therapeutic Medicine, 2016, v. 11, n. 5, p. 1781, doi. 10.3892/etm.2016.3133

By:

MOTOYUKI KOHJIMA;
MIHO KUROKAWA;
MUNECHIKA ENJOJI;
TSUYOSHI YOSHIMOTO;
TSUKASA NAKAMURA;
TOMOKO OHASHI;
KUNITAKA FUKUIZUMI;
NAOHIKO HARADA;
YUSUKE MURATA;
KAZUHISA MATSUNAGA;
MASAKI KATO;
KAZUHIRO KOTOH;
MAKOTO NAKAMUTA

Publication type:

Article

Telaprevir-based triple therapy following partial splenic arterial embolization for chronic hepatitis C with thrombocytopenia can reduce carcinogenesis and improve hepatic function reserve.

Published in:

Experimental & Therapeutic Medicine, 2015, v. 10, n. 4, p. 1334, doi. 10.3892/etm.2015.2674

By:

TORU ISHIKAWA;
SATOSHI ABE;
YUICHI KOJIMA;
RYOKO HORIGOME;
TOMOE SANO;
AKITO IWANAGA;
KEIICHI SEKI;
TERASU HONMA;
TOSHIAKI YOSHIDA

Publication type:

Article

Protease inhibitors to treat hepatitis C in the Swiss HIV Cohort Study: high efficacy but low treatment uptake.

Published in:

HIV Medicine, 2015, v. 16, n. 10, p. 599, doi. 10.1111/hiv.12269

By:

Schaerer, V;
Haubitz, S;
Kovari, H;
Ledergerber, B;
Ambrosioni, J;
Cavassini, M;
Stoeckle, M;
Schmid, P;
Decosterd, L;
Aouri, M;
Böni, J;
Günthard, HF;
Furrer, H;
Metzner, KJ;
Fehr, J;
Rauch, A

Publication type:

Article

Virological response rates for telaprevir-based hepatitis C triple therapy in patients with and without HIV coinfection.

Published in:

HIV Medicine, 2014, v. 15, n. 2, p. 108, doi. 10.1111/hiv.12086

By:

Martel ‐ Laferrière, V;
Brinkley, S;
Bichoupan, K;
Posner, S;
Stivala, A;
Perumalswami, P;
Schiano, TD;
Sulkowski, M;
Dieterich, DT;
Branch, AD

Publication type:

Article

Virological outcomes and treatment algorithms utilisation in observational study of patients with chronic hepatitis C treated with boceprevir or telaprevir.

Published in:

Alimentary Pharmacology & Therapeutics, 2015, v. 41, n. 7, p. 671, doi. 10.1111/apt.13095

By:

Sterling, R. K.;
Kuo, A.;
Rustgi, V. K.;
Sulkowski, M. S.;
Stewart, T. G.;
Fenkel, J. M.;
El‐Genaidi, H.;
Mah'moud, M. A.;
Abraham, G. M.;
Stewart, P. W.;
Akushevich, L.;
Nelson, D. R.;
Fried, M. W.;
Di Bisceglie, A. M.

Publication type:

Article

Telaprevir or boceprevir triple therapy in patients with chronic hepatitis C and varying severity of cirrhosis.

Published in:

Alimentary Pharmacology & Therapeutics, 2014, v. 39, n. 10, p. 1213, doi. 10.1111/apt.12718

By:

Saxena, V.;
Manos, M. M.;
Yee, H. S.;
Catalli, L.;
Wayne, E.;
Murphy, R. C.;
Shvachko, V. A.;
Pauly, M. P.;
Chua, J.;
Monto, A.;
Terrault, N. A.

Publication type:

Article

Commentary: detection of low level viraemia in telaprevir-based triple therapy for hepatitis C virus.

Published in:

Alimentary Pharmacology & Therapeutics, 2014, v. 39, n. 5, p. 543, doi. 10.1111/apt.12610

By:

Elsharkawy, A. M.

Publication type:

Article

Commentary: real-world triple therapy experience treating hepatitis C virus.

Published in:

Alimentary Pharmacology & Therapeutics, 2014, v. 39, n. 5, p. 542, doi. 10.1111/apt.12599

By:

Heron, T.;
Miller, M. H.;
Dillon, J. F.

Publication type:

Article

Commentary: detection of low level viraemia in telaprevir-based triple therapy for hepatitis C virus - authors' reply.

Published in:

Alimentary Pharmacology & Therapeutics, 2014, v. 39, n. 5, p. 544, doi. 10.1111/apt.12642

By:

Maasoumy, B.;
Wedemeyer, H.

Publication type:

Article

Comparative effectiveness of the hepatitis C virus protease inhibitors boceprevir and telaprevir in a large U.S. cohort.

Published in:

Alimentary Pharmacology & Therapeutics, 2014, v. 39, n. 1, p. 93, doi. 10.1111/apt.12546

By:

Backus, L. I.;
Belperio, P. S.;
Shahoumian, T. A.;
Cheung, R.;
Mole, L. A.

Publication type:

Article

Detection of low HCV viraemia by repeated HCV RNA testing predicts treatment failure to triple therapy with telaprevir.

Published in:

Alimentary Pharmacology & Therapeutics, 2014, v. 39, n. 1, p. 85, doi. 10.1111/apt.12544

By:

Maasoumy, B.;
Cobb, B.;
Bremer, B.;
Luk, K.;
Halfon, P.;
Aslam, S.;
Manns, M. P.;
Cornberg, M.;
Wedemeyer, H.

Publication type:

Article

Commentary: triple therapy for patients with chronic hepatitis C and advanced fibrosis?

Published in:

Alimentary Pharmacology & Therapeutics, 2013, v. 38, n. 11/12, p. 1407, doi. 10.1111/apt.12526

By:

Ferenci, P.

Publication type:

Article

Telaprevir-based triple therapy for chronic hepatitis C patients with advanced fibrosis: a prospective clinical study.

Published in:

Alimentary Pharmacology & Therapeutics, 2013, v. 38, n. 9, p. 1076, doi. 10.1111/apt.12494

By:

Ogawa, E.;
Furusyo, N.;
Nakamuta, M.;
Kajiwara, E.;
Nomura, H.;
Dohmen, K.;
Takahashi, K.;
Satoh, T.;
Azuma, K.;
Kawano, A.;
Tanabe, Y.;
Kotoh, K.;
Shimoda, S.;
Hayashi, J.

Publication type:

Article

Durability of SVR in chronic hepatitis C patients treated with peginterferon-α2a/ribavirin in combination with a direct-acting anti-viral.

Published in:

Alimentary Pharmacology & Therapeutics, 2013, v. 38, n. 2, p. 118, doi. 10.1111/apt.12350

By:

Rutter, K.;
Hofer, H.;
Beinhardt, S.;
Dulic, M.;
Gschwantler, M.;
Maieron, A.;
Laferl, H.;
Stättermayer, A. F.;
Scherzer, T.‐M.;
Strassl, R.;
Holzmann, H.;
Steindl‐Munda, P.;
Ferenci, P.

Publication type:

Article

Health-related quality of life in genotype 1 treatment-naïve chronic hepatitis C patients receiving telaprevir combination treatment in the ADVANCE study.

Published in:

Alimentary Pharmacology & Therapeutics, 2013, v. 38, n. 2, p. 124, doi. 10.1111/apt.12354

By:

Vera‐Llonch, M.;
Martin, M.;
Aggarwal, J.;
Donepudi, M.;
Bayliss, M.;
Goss, T.;
Younossi, Z.

Publication type:

Article

New Therapies for Hepatitis C: Considerations in Patients with Renal Impairment.

Published in:

2014

By:

Zimner-Rapuch, Sarah;
Janus, Nicolas;
Deray, Gilbert;
Launay-Vacher, Vincent

Publication type:

Journal Article

Outcomes of treatment with direct-acting antivirals for infection with hepatitis C virus genotypes 1-4 in an ambulatory care setting.

Published in:

American Journal of Health-System Pharmacy, 2017, v. 74, p. S1, doi. 10.2146/ajhp160567

By:

Bach, Timothy A.;
Zaiken, Kathy

Publication type:

Article

Apparent interaction between telaprevir and warfarin in a patient with chronic hepatitis C viral infection.

Published in:

2012

By:

Gatti, Danielle C.;
Cha, Agnes

Publication type:

Case Study